ARGX Stock: Price, Earnings History and SEC Filings
argenx SE (ARGX) last traded at $892.87, down 0.55% on the latest session and down 6.9% over the past month. In its most recent reported quarter (Sep 2026) earnings per share were $7.80 against an analyst estimate of $7.44, a beat of 4.8%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
ARGX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Sep 2026 | Oct 22, 2026 | $7.80 | $7.44 | +4.84% |
| Jun 2026 | Jul 23, 2026 | $7.32 | $6.13 | +19.41% |
| Mar 2026 | May 7, 2026 | $5.52 | $5.16 | +6.98% |
| Dec 2025 | Feb 26, 2026 | $8.02 | $6.24 | +28.53% |
ARGX beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for ARGX
Insider filing activity
ARGX insiders filed 0 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
ARGX news
- HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Oct 30, 2026 · finance.yahoo.com
- European Equities Traded in the US as American Depositary Receipts Rise in Thursday TradingOct 29, 2026 · finance.yahoo.com
- argenx (ENXTBR:ARGX) Stock Looks Overvalued After Its 202% Five Year RunOct 25, 2026 · finance.yahoo.com
- argenx (ENXTBR:ARGX) Posted Q3 2026 Results, Is It Fully Priced?Oct 25, 2026 · finance.yahoo.com
- argenx (ENXTBR:ARGX) Reports Positive Phase 3 Data In Autoimmune MyositisOct 24, 2026 · finance.yahoo.com
- Argenx (ENXTBR:ARGX) Stock Faces Margin Questions After Q3 EarningsOct 24, 2026 · finance.yahoo.com
- Argenx's Vyvgart Sales Growth, Pipeline Progress Support Outlook, Oppenheimer SaysOct 23, 2026 · finance.yahoo.com
- Argenx's Vyvgart Beats Expectations With Focus Shifting to December Data, RBC SaysOct 23, 2026 · finance.yahoo.com
About argenx SE
argenx SE (ARGX) is a US-listed public company on Nasdaq. The SEC classifies its business as Biological Products (no Diagnostic Substances). It is incorporated in Netherlands. Its fiscal year ends in December.